Skip to main content

FATE THERAPEUTICS INC

corporate_fare Company Profile

FATE THERAPEUTICS INC

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed FATE - Latest Insights

FATE
Feb 26, 2026, 9:07 AM EST
Filing Type: 10-K
Importance Score:
8
FATE
Feb 26, 2026, 9:04 AM EST
Filing Type: 8-K
Importance Score:
9